Podda A - Search Results

1

What are the limits of adjuvanticity?

Del Giudice G, Podda A, Rappuoli R. Del Giudice G, et al. Among authors: podda a. Vaccine. 2001 Oct 15;20 Suppl 1:S38-41. doi: 10.1016/s0264-410x(01)00288-2. Vaccine. 2001. PMID: 11587808

2

Towards third-generation whooping cough vaccines.

Rappuoli R, Pizza M, Podda A, De Magistris MT, Nencioni L. Rappuoli R, et al. Among authors: podda a. Trends Biotechnol. 1991 Jul;9(7):232-8. doi: 10.1016/0167-7799(91)90076-t. Trends Biotechnol. 1991. PMID: 1370047 Review.

3

Recombinant acellular pertussis vaccine--from the laboratory to the clinic: improving the quality of the immune response.

Rappuoli R, Pizza M, Covacci A, Bartoloni A, Nencioni L, Podda A, De Magistris MT. Rappuoli R, et al. Among authors: podda a. FEMS Microbiol Immunol. 1992 Oct;5(4):161-70. doi: 10.1111/j.1574-6968.1992.tb05898.x. FEMS Microbiol Immunol. 1992. PMID: 1384602

4

Progress towards the development of new vaccines against whooping cough.

Rappuoli R, Podda A, Pizza M, Covacci A, Bartoloni A, de Magistris MT, Nencioni L. Rappuoli R, et al. Among authors: podda a. Vaccine. 1992;10(14):1027-32. doi: 10.1016/0264-410x(92)90112-w. Vaccine. 1992. PMID: 1471424 Review.

5

Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C.

Costantino P, Viti S, Podda A, Velmonte MA, Nencioni L, Rappuoli R. Costantino P, et al. Among authors: podda a. Vaccine. 1992;10(10):691-8. doi: 10.1016/0264-410x(92)90091-w. Vaccine. 1992. PMID: 1523880 Clinical Trial.

6

Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: safety and immunogenicity in 12- to 24- and 2- to 4-month-old children.

Podda A, De Luca EC, Titone L, Casadei AM, Cascio A, Peppoloni S, Volpini G, Marsili I, Nencioni L, Rappuoli R. Podda A, et al. J Pediatr. 1992 May;120(5):680-5. doi: 10.1016/s0022-3476(05)80227-6. J Pediatr. 1992. PMID: 1578301

7

Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa.

Podda A, Nencioni L, Marsili I, Peppoloni S, Volpini G, Donati D, Di Tommaso A, De Magistris MT, Rappuoli R. Podda A, et al. Vaccine. 1991 Oct;9(10):741-5. doi: 10.1016/0264-410x(91)90290-m. Vaccine. 1991. PMID: 1759492 Clinical Trial.

8

Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.

Podda A, Bona G, Canciani G, Pistilli AM, Contu B, Furlan R, Meloni T, Stramare D, Titone L, Rappuoli R, et al. Podda A, et al. J Pediatr. 1995 Aug;127(2):238-43. doi: 10.1016/s0022-3476(95)70301-2. J Pediatr. 1995. PMID: 7636648 Clinical Trial.

9

Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. The Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.

Podda A, De Luca EC, Contu B, Furlan R, Maida A, Moiraghi A, Stramare D, Titone L, Uxa F, Di Pisa F, Peppoloni S, et al. Podda A, et al. J Pediatr. 1994 Jun;124(6):921-6. doi: 10.1016/s0022-3476(05)83181-6. J Pediatr. 1994. PMID: 8201477 Clinical Trial.

10

Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.

Podda A, Carapella De Luca E, Titone L, Casadei AM, Cascio A, Bartalini M, Volpini G, Peppoloni S, Marsili I, Nencioni L, et al. Podda A, et al. J Pediatr. 1993 Jul;123(1):81-4. doi: 10.1016/s0022-3476(05)81543-4. J Pediatr. 1993. PMID: 8320630

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results